12 Sep 2009
, Chennai, India
: Orchid today announced the settlement of the patent litigation between Orchid and Schering-Plough relating to Desloratadine Tablets, 5 mg and Desloratadine 2.5 mg and 5 mg Orally Disintegrating Tablets (ODT), the generic versions of Schering-Plough's Clarinex® and Clarinex® RediTabs® allergy medication. The litigation has been pending in the U.S. District Court of New Jersey since September 2006.
Pursuant to the settlement, Orchid will have the right to market Desloratadine Tablets, 5 mg and Desloratadine 2.5 mg and 5 mg Orally Disintegrating Tablets in the U.S. on July 01, 2012 and January 01, 2012 respectively or earlier in certain circumstances, provided that the U.S. Food and Drug Administration (FDA) approves Orchid's abbreviated new drug applications (ANDAs) of the above mentioned products. Orchid's products may be the prescription form or over-the-counter version products depending on the status of Clarinex® and Clarinex RediTabs® at the time. Additional terms of the settlement are confidential, and the agreement is subject to review by the Department of Justice and the Federal Trade Commission. |
|
